Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...Allows for More Efficient Construction of Syntheti...wswire-USNewswire/ -- Researchers at the J. Craig ...research organization, have published a paper desc... which the team can now assemble the whole bacteri...om 25 fragments of DNA. Lead author Daniel G. Gibs...
(Date:12/4/2008)...DERDALE, Fla., Dec. 4 Im...rd: IMDS), a pioneer in laser optical breast,imag...he CTLM system as an,adjunct to mammography is fe...iology. , (Logo: http://www.newscom.com/c...ellinger, MD, a radiologist at Charite Hospital in...
(Date:12/4/2008)...BURG, Md., Dec. 4 MedImmune today ...l trial in patients with chronic asthma to,determ...ed monoclonal antibody,(MAb) that targets the int...gest that inhibiting the IL-5R pathway may lead to...sthma, supporting continued study of this antibody...
(Date:12/4/2008)...mpany Introduces New Trade Name Onrigin(TM) for La...ewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ...ouncements related to events in connection with th...ng at the Moscone Center in San Francisco from Dec...tation , , The Company announced that it ...
Breaking Biology Technology:J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 2J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 3J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 4J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 5Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 4
...WAUKEE - ARI Network Services, Inc., a provider...gy and services for equipment dealers, on Wednesda...e for the fiscal year ended July 31, 2005. , ,Rev...rease from revenues of $13.4 million in fiscal 200...or $0.32 per diluted share, from operating income ...
...nomowoc, Wis. - These are not your parents, gener...go, the word "cool" was rarely heard to cross the ...ves. Today, cool is a marketable commodity. The pr... the Olympia Resort on Thursday, several dozen rep... groups met to brainstorm strategies for making Wi...
...kesha, Wis. -- Profits for General Electric Co.,s...third quarter behind an 8 percent growth in total ...are -- the London-based parent of GE Healthcare Te... billion for the second quarter, up 7 percent comp...ago. , ,Profits for GE Healthcare rose to $589 mil...
...ison, Wis. - A group of private colleges and univ...ministrative information technology platform using... ,Jenzabar on Monday reported an agreement with th...nd Universities to use a number of its systems. T...s Internet Campus Solution and Jenzabar,s Learning...
Other Biology Technology:Tech leaders call for more creativity 2
(Date:12/3/2008).... The first 5-year forest inventory report for Cal...e to the public: California,s Forest Resources, 20...eport., Here are some key findings from the repor...s 100 million acres;19 million acres is publicly m...rface account for most of the housing growth in th...
(Date:12/3/2008)...od is big and heavy, with seemingly little prayer ... yet, like a grounded teenager who knows where the...onable chance of escape. , University of Florida...mental landscape devoted to wildlife corridors gr...ve discovered the pea and similar species share, g...
(Date:12/3/2008)...tion of Oceanography at UC San Diego returning fro...recedented details of vibrant sea life and ecosyst...tions of new species and marine animals previously...uded surveys at unexplored depths, have revealed d...dence that human impacts have stretched down deepl...
(Date:12/3/2008)...As the United States continues to develop alternat...dence, cellulosic-based ethanol has emerged as one...n stover remains the most popular source available...ated with the removal of corn fodder as a cellulos...nmental concern. , In the November-December 20...
Breaking Biology News(10 mins):Forest inventories in California include more than trees 2Forest inventories in California include more than trees 3Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4Managing carbon loss 2CEO Proposes a Radical Plan to Revamp the Healthcare System 27499 1CEO Proposes a Radical Plan to Revamp the Healthcare System 27499 2CEO Proposes a Radical Plan to Revamp the Healthcare System 27499 3Sarasota Cosmetic Dentistry Practice Wins Big At FACD 27496 1Sarasota Cosmetic Dentistry Practice Wins Big At FACD 27496 2Quadriplegic Man Defied the Odds Continues to Inspire 27493 1Quadriplegic Man Defied the Odds Continues to Inspire 27493 2Quadriplegic Man Defied the Odds Continues to Inspire 27493 3Educational materials can alter young womens attitudes about tanning may reduce skin cancer 27491 1Educational materials can alter young womens attitudes about tanning may reduce skin cancer 27491 2
...ividual,s immune system controls HIV during the ea...th the specific versions of key immune-system mole... as well as on the fragments of viral protein thos...lly destroy infected cells. In a report in the No...e Partners AIDS Research Center at Massachusetts G...
...the ironic name "Srcasm" can counteract the effect...rding to new research by investigators at the Univ...nimal models, the researchers discovered that Srca...ng uncontrolled cell growth caused by a family of ...ed online in the Journal of Biological Chemistry, ...
...tients suffering chronic obstructive pulmonary dis...rs, a new finding that contradicts the conventiona...The study "Evidence for attempted regional elastic...son Woods, Kristin Castillo, Alexander Patterson a...uis, Mo.; Joel Cooper of the University of Pennsyl...
...of human neurons may have been a key factor in why...primate relatives. In a study comparing the genome...es, researchers at the U.S. Department of Energy,s...ab) and Joint Genome Institute (JGI) found a strik...quences that appear to regulate genes involved in ...
Other Biology News:Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3Signal protein shows promise for blocking tumor promoters in skin cells 2Lungs try to repair damaged elastic fibers 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections.
... identified as the cellular homolog of the avian s...been shown to be almost identical to c-Jun in thei...zation and DNA binding, whereas their N-terminal d...vation, diverge. Antigen: The antibody was pro...
Rnase Inhibitor from Bioline
Rabbit polyclonal to JAK2 (phospho Y1007) ( Abpromise for all tested applications). Antigen: Synthesized phosphopeptide derived from human JAK2 around the phosphorylation site of tyrosine 1007 (
Biology Products: